• 1992 – 1994
  Invention and introduction of the positron emitter ⁹⁴Tc

• 1994 – 1999
  Invention and introduction of the positron emitter ⁸⁶Y vs. ⁹⁰Y-anlogue therapeuticals and its first use as THERANOSTICS 

• 1998
  Establishment of the first GMP compliant radiopharmaceutical production site at the Johannes Gutenberg University and in the state of Rheinland-Pfalz (Rhineland-Palatinate) located in the Institute of Nuclear Chemistry 

• 1996 – 2000
  Establishment of the first clinical PET studies at the Johannes Gutenberg University and in the state of Rheinland-Pfalz (Rhineland-Palatinate) located in the Institute of Nuclear Chemistry 

• 2000 – now
  Invention and translational clinical application of several potent ¹⁸F-labelled neurotransmitter analogs for PET/CT in the living brain, mainly relevant to psychiatry

• 2000
  Invention of the production strategy of carrier-free ¹⁷⁷Lu via the ¹⁷⁶Yb-route

• 2004
  Establishment of the cation exchange-based ⁶⁸Ge/⁶⁸Ga radionuclide generator processing

• 2004
  Invention and introduction of the ⁴⁴Ti/⁴⁴Sc Generator

• 2006 – 2009
  Transfer of ⁶⁸Ge/⁶⁸Ga generator technologies and medical applications to:
  Bad Berka (Germany), New Delhi (India), Santiago (Chile), Melbourne, Fremantle and Sydney (Australia)

• Since 2007
  Organisation of several international Training schools on PET-radionuclide generators for trivalent metals: ⁶⁸Ge/⁶⁸Ga and ⁴⁴Ti/⁴⁴Sc at Mainz and elsewhere

• 2011
  Together with Prof. Richard Baum initiator and coordinator of a World Congresses on Gallium-68 and Peptide Receptor RadioNuclide Therapy (PRRNT) – on the way to personalized medicine: Bad Berka and Mainz, Germany, June 23-28, 2011

• 2011 – now
  Together with Prof. Richard Baum coordinator of a series of Theranostic World Congresses following the Bad Berka congress in 2011:
  2^nd in Chandigarh, India (2013)
  3^rd in Baltimore, USA, (2015)
  4^th in Melbourne, Australia (2017)
  5^th in Jeju, Korea (2019)
  6^th Wiesbaden, Germany (2022)
  … to be continued …

• 2008 – 2018
  Invention and introduction of a new class of radiolabeled bisphosphonates for imaging and therapy of bone metastases

• 2008 – now
  Invention of a labeling precursor with one or more targeting vectors as radiopharmaceuticals

• 2010 – now
  Invention and introduction of new classes of bifunctional chelators (DATA and AAZTA) ready for instant kit-type production of radiometal-labelled pharmaceuticals, and providing a platform for a variety of new theranostics

• 2010 – 2016
  Systematic physico-chemical investigations on the impact of non-aqueous solvents on the formation of radiometal-ligand complex and its impact on the synthesis of radiopharmaceuticals

• 2010 – 2016
  Systematic investigations on the separation and analytics when separating two neighbored radio-lanthanides, two radio-isotopes of the same chemical element and even two different excited nuclear states of the same radioisotope

• 2018
  Installation of a cyclotron at the Institute of Nuclear Chemistry, the first in the state of Rheinland-Pfalz (Rhineland-Palatinate)

• 2020 – now
  Invention and introduction of new classes of theranostics based on FAP inhibitors

for
basic inorganic radiochemistry   

and
physic-chemistry of radio-metals in aqueous solutions 

to
production of radionuclides at cyclotrons and reactors (such as. e.g. suggesting the positron emitters ⁸⁶Y and ^94mTc or creating the pathway of nca. ¹⁷⁷Lu via the ¹⁶⁹Yb(n,γ) route) including measurements of nuclear data and development of radiochemical separation methods 

and
design of various radionuclide generator systems (recently the post-processing of the ⁶⁸Ge/⁶⁸Ga-system or the realization of the ⁴⁴Ti/⁴⁴Sc generator)

plus
Synthesis of new radiopharmaceuticals for theranostics, such as a new class of radiolabeled bisphosphonates for imaging and therapy of bone metastases, ⁶⁸Ga- und ¹⁷⁷Lu labeled pharmaceuticals based on FAP inhibitors for imaging and therapy of different tumor types.